This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Antibiotics in osteomyelitis and septic arthritis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Consult expert advice.

Antibiotic treatment is usually necessary for up to 6 weeks in septic arthritis and 2-3 months in osteomyelitis.

  • antibiotic regimen used is dictated by any local specific bacterial resistance
  • antibiotic of choice should be able to treat Staph. aureus and other Gram-positive cocci in adults (e.g. flucloxacillin and fusidic acid, clindamycin; but Staph. aureus is exhibiting increasing resistance to ß-lactam antibiotics), H. influenzae in children under 3 years of age (e.g. amoxicillin, a cephalosporin such as cefotaxime or ceftriaxone) or Gram-negative organisms in the elderly and in those with predisposing diseases such as RA (e.g. a cephalopsorin such as cefotaxime or ceftriaxone)
  • important not to start an antibiotic until bacterial culture samples have been taken and do not give the antibiotic by injection into the joint
  • response to therapy may be judged by the clinical features, fever, acute phase markers (e.g. CRP), and white cell count

Note: these are merely guidelines; please check with local microbiological advice and the current issue of BNF.

Reference:

  • (1) Axford JS. Joint and bone infections Medicine 2006;34 (10):405-412.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.